An antibody drug study by Eli Lilly and Company has shown that the coronavirus antibody LY-CoV555, developed by Indianapolis-based Lilly and the Canadian company AbCellera, prevents mild to moderately ill coronavirus patients from being hospitalized. The antibody is reported to work by recognizing the virus once a person is infected and attaching to it, which prevents the pathogen from spreading throughout the body.
Myron Cohen, MD, the Yeargan-Bate Distinguished Professor of Medicine, Microbiology and Immunology, and Epidemiology, said he was “strongly encouraged” by the results in the Daily Mail UK.
“This seems to demonstrate what we thought – that such drugs would give a benefit, Cohen said in the article.
Although he had no role in the Lilly study, Cohen is directing antibody studies for a public-private research group the federal government formed to speed testing of these drugs.
Read the article here.